Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital, 25 rue du Bugnon, 1011, Lausanne, Switzerland.
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Virchows Arch. 2018 Oct;473(4):435-441. doi: 10.1007/s00428-018-2366-5. Epub 2018 May 2.
The molecular alterations of pancreatic acinar cell carcinomas (ACCs) and mixed acinar-neuroendocrine carcinomas (MANECs) are not completely understood, and the possible role of c-MYC amplification in tumor development, progression, and prognosis is not known. We have investigated c-MYC gene amplification in a series of 35 ACCs and 4 MANECs to evaluate its frequency and a possible prognostic role. Gene amplification was investigated using interphasic fluorescence in situ hybridization analysis simultaneously hybridizing c-MYC and the centromere of chromosome 8 probes. Protein expression was immunohistochemically investigated using a specific monoclonal anti-c-myc antibody. Twenty cases had clones with different polysomies of chromosome 8 in absence of c-MYC amplification, and 5 cases had one amplified clone and other clones with chromosome 8 polysomy, while the remaining 14 cases were diploid for chromosome 8 and lacked c-MYC amplification. All MANECs showed c-MYC amplification and/or polysomy which were observed in 54% pure ACCs. Six cases (15.3%) showed nuclear immunoreactivity for c-myc, but only 4/39 cases showed simultaneous c-MYC amplification/polysomy and nuclear protein expression. c-myc immunoreactivity as well as c-MYC amplification and/or chromosome 8 polysomy was not statistically associated with prognosis. Our study demonstrates that a subset of ACCs shows c-MYC alterations including gene amplification and chromosome 8 polysomy. Although they are not associated with a different prognostic signature, the fact that these alterations are present in all MANECs suggests a role in the acinar-neuroendocrine differentiation possibly involved in the pathogenesis of MANECs.
胰腺腺泡细胞癌 (ACC) 和混合性腺泡-神经内分泌癌 (MANEC) 的分子改变尚不完全清楚,c-MYC 扩增在肿瘤发生、进展和预后中的可能作用也尚不清楚。我们研究了一系列 35 例 ACC 和 4 例 MANEC 中的 c-MYC 基因扩增,以评估其频率及其可能的预后作用。使用间期荧光原位杂交分析同时杂交 c-MYC 和 8 号染色体着丝粒探针来研究基因扩增。使用特异性单克隆抗 c-myc 抗体进行免疫组织化学研究来检测蛋白表达。20 例病例在没有 c-MYC 扩增的情况下存在不同的 8 号染色体多倍体克隆,5 例病例存在一个扩增克隆和其他 8 号染色体多倍体克隆,而其余 14 例病例为 8 号染色体二倍体且缺乏 c-MYC 扩增。所有 MANEC 均显示 c-MYC 扩增和/或多倍体,54%的纯 ACC 中观察到 c-MYC 扩增和/或多倍体。6 例(15.3%)病例显示核 c-myc 免疫反应性,但仅 4/39 例同时显示 c-MYC 扩增/多倍体和核蛋白表达。c-myc 免疫反应性以及 c-MYC 扩增和/或 8 号染色体多倍体与预后无统计学关联。我们的研究表明,一部分 ACC 显示包括基因扩增和 8 号染色体多倍体在内的 c-MYC 改变。尽管它们与不同的预后特征无关,但这些改变存在于所有 MANEC 中,提示它们可能在腺泡-神经内分泌分化中起作用,可能参与 MANEC 的发病机制。
Arch Pathol Lab Med. 2020-7-1
Comb Chem High Throughput Screen. 2024
World J Gastroenterol. 2022-10-28
J Pathol Transl Med. 2022-11
Genes Chromosomes Cancer. 2022-12
World J Gastroenterol. 2022-5-21
World J Gastroenterol. 2022-2-28
Pediatr Blood Cancer. 2022-2
Virchows Arch. 2022-2
Front Oncol. 2017-9-21
Nat Rev Cancer. 2015-9-18
Front Med (Lausanne). 2015-6-15